Collegium Pharmaceutical (COLL) Retained Earnings (2014 - 2026)

Collegium Pharmaceutical has reported Retained Earnings for 13 years, with the latest figure at $636.1 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 6.2% year-over-year to $636.1 million in Q2 2026; TTM through Jun 2026 was $636.1 million, a 6.2% increase from a year earlier, with the FY2025 full-year figure at $625.0 million, up 5.88% from the prior year.
• Retained Earnings was $636.1 million for Q2 2026 at Collegium Pharmaceutical, up from $621.7 million in the prior quarter.
• The five-year high for Retained Earnings was $636.1 million in Q2 2026, with the low at $513.3 million in Q1 2022.
• Average Retained Earnings over 5 years is $571.9 million, with a median of $567.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings gained 7.17% in 2022, then increased 3.55% in 2024.
• Over 5 years, Retained Earnings stood at $538.1 million in 2022, then rose by 5.18% to $565.9 million in 2023, then climbed by 4.29% to $590.3 million in 2024, then advanced by 5.88% to $625.0 million in 2025, then increased by 1.78% to $636.1 million in 2026.
• The last three Retained Earnings figures came in at $636.1 million (Q2 2026), $621.7 million (Q1 2026), and $625.0 million (Q4 2025), per Business Quant data.